{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:14:15Z","timestamp":1783682055879,"version":"3.55.0"},"reference-count":21,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Head and neck cancer patients undergoing concurrent chemoradiation treatment (CCRT) lose a significant amount of lean soft tissue mass (LSTM) reducing muscle strength and performance. Progressive resistance training (PRT) may mitigate this loss and improve muscle strength and performance. The purpose was to investigate the effects of PRT initiated at CCRT onset on LSTM, muscle strength, and functional performance compared with usual care.\nPatients\/material and methods: Patients were randomized to 12 weeks of PRT (36 sessions) or usual care with no exercise (control group [CON]). At baseline, after 6 and 12 weeks, 6 and 12 months, Dual-Energy Absorptiometry evaluated total body mass (BM), LSTM, and fat mass (FM); 1 repetition maximum (1RM) chest press and leg press test assessed maximal muscle strength and functional performance (30 seconds chair-rise; 30 seconds arm curls; stair climb) was evaluated. Dietary intake was registered as were Quality of Life questionnaires European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) C30 and QLQ H&amp;N-35. A sample size of 72 patients (36 per group) was determined a priori with LSTM as the primary endpoint.\nResults: Fifty patients were included (required sample size was not met), 25 in each group. From baseline to 12 weeks, patients in the PRT group lost 8.6 \u00b1 1.0 kg BM (10%), 3.4 \u00b1 0.6 kg LSTM (6%), and 5.2 \u00b1 0.8 kg FM (21%). This was not significantly different from the CON group losing 7.4 \u00b1 1.0 kg BM (9%), 3.4 \u00b1 0.6 kg LSTM (6%), and 4.0 \u00b1 0.8 FM (17%). Likewise, 1RM decreased equally in both groups. Chair rise and arm curl performance improved significantly more in PRT compared with in CON (p &lt; 0.05).\nInterpretation: In this study PRT initiated at CCRT onset did not attenuate loss of LSTM or muscle strength. However, PRT did result in significantly increased functional performance.<\/jats:p>","DOI":"10.2340\/1651-226x.2026.45545","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:27:02Z","timestamp":1783679222000},"page":"599-608","source":"Crossref","is-referenced-by-count":0,"title":["The effect of progressive resistance training on lean soft tissue mass in head and neck cancer patients during concomitant chemoradiotherapy: the DAHANCA 31 randomized controlled trial"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9692-0839","authenticated-orcid":false,"given":"Camilla K.","family":"Lonkvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-3191","authenticated-orcid":false,"given":"Simon","family":"L\u00f8nbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-3102","authenticated-orcid":false,"given":"Anders","family":"Vinther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3457-6249","authenticated-orcid":false,"given":"Bo","family":"Zerahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rosenbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-0612","authenticated-orcid":false,"given":"Mads Vandsted","family":"Svart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-6992","authenticated-orcid":false,"given":"Morten Lyng","family":"H\u00f8gild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3562-0026","authenticated-orcid":false,"given":"Hanne","family":"Primdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-0210","authenticated-orcid":false,"given":"Julie","family":"Gehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"162501","doi-asserted-by":"crossref","unstructured":"L\u00f8nbro S, Gam S, Hermann AP, Hansen CR, Johansen J. Accelerated loss of lean body mass in head and neck cancer patients during cisplatin-based chemoradiation. Acta Oncol. 2023;62:1403\u201311.","DOI":"10.1080\/0284186X.2023.2245558"},{"key":"162502","doi-asserted-by":"crossref","unstructured":"Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S. Characterization of changes in total body composition for head and neck cancer patients undergoing chemoradiotherapy using dual-energy X-ray absorptiometry (DEXA). Head Neck. 2013;36:1356\u201362.","DOI":"10.1002\/hed.23461"},{"key":"162503","doi-asserted-by":"crossref","unstructured":"Wang Y, Zheng B, Zhang L, Zhang T, Zhao D, Sun Y, et al. Impact of sarcopenia and obesity on overall survival in patients with head and neck cancer receiving radiotherapy: a longitudinal study. Eur J Oncol Nurs. 2024;72:102679.","DOI":"10.1016\/j.ejon.2024.102679"},{"key":"162504","doi-asserted-by":"crossref","unstructured":"Ferr\u00e3o B, Neves PM, Santos T, Capelas ML, M\u00e4kitie A, Ravasco P. Body composition changes in patients with head and neck cancer under active treatment: a scoping review. Support Care Cancer. 2020;28:4613\u201325.","DOI":"10.1007\/s00520-020-05487-w"},{"key":"162505","doi-asserted-by":"crossref","unstructured":"Almada-Correia I, Neves PM, M\u00e4kitie A, Ravasco P. Body composition evaluation in head and neck cancer patients: a review. Front Oncol. 2019;9:1112.","DOI":"10.3389\/fonc.2019.01112"},{"key":"162506","doi-asserted-by":"crossref","unstructured":"Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 2012;103:69\u201375.","DOI":"10.1016\/j.radonc.2012.01.002"},{"key":"162507","doi-asserted-by":"crossref","unstructured":"Grossberg AJ, Chamchod S, Fuller CD, Mohamed ASR, Heukelom J, Eichelberger H, et al. Association of body composition with survival and locoregional control of radiotherapy-treated head and neck squamous cell carcinoma. JAMA Oncol. 2016;2:1307\u201314.","DOI":"10.1001\/jamaoncol.2015.6339"},{"key":"162508","doi-asserted-by":"crossref","unstructured":"L\u00f8nbro S, Dalgas U, Primdahl H, Johansen J, Nielsen JL, Overgaard J, et al. Lean body mass and muscle function in head and neck cancer patients and healthy individuals \u2013 results from the DAHANCA 25 study. Acta Oncol. 2013;52:1543\u201351.","DOI":"10.3109\/0284186X.2013.822553"},{"key":"162509","doi-asserted-by":"crossref","unstructured":"L\u00f8nbro S, Dalgas U, Primdahl H, Overgaard J, Overgaard K, L\u00f8nbro S, et al. Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients \u2013 the DAHANCA 25A study. Acta Oncol. 2013;52:310\u201318.","DOI":"10.3109\/0284186X.2012.741325"},{"key":"162510","doi-asserted-by":"crossref","unstructured":"L\u00f8nbro S, Dalgas U, Primdahl H, Johansen J, Nielsen JL, Aagaard P, et al. Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy \u2013 results from the randomized DAHANCA 25B trial. Radiother Oncol. 2013;108:314\u201319.","DOI":"10.1016\/j.radonc.2013.07.002"},{"key":"162511","doi-asserted-by":"crossref","unstructured":"Avancini A, Borsati A, Belluomini L, Giannarelli D, Nocini R, Insolda J, et al. Effect of exercise across the head and neck cancer continuum: a systematic review of randomized controlled trials. Support Care Cancer. 2023;31:620.","DOI":"10.1007\/s00520-023-08126-2"},{"key":"162512","doi-asserted-by":"crossref","unstructured":"Lonkvist CK, Vinther A, Zerahn B, Rosenbom E, Deshmukh AS, Hojman P, et al. Progressive resistance training in head and neck cancer patients undergoing concomitant chemoradiotherapy. Laryngoscope Investig Otolaryngol. 2017;2:295\u2013306.","DOI":"10.1002\/lio2.88"},{"key":"162513","doi-asserted-by":"crossref","unstructured":"Lonkvist CK, L\u00f8nbro S, Vinther A, Zerahn B, Rosenbom E, Primdahl H, et al. Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy \u2013 design of the DAHANCA 31 randomized trial. BMC Cancer. 2017;17:346.","DOI":"10.1186\/s12885-017-3388-0"},{"key":"162514","doi-asserted-by":"crossref","unstructured":"Aadahl M, J\u00f8rgensen T. Validation of a new self-report instrument for measuring physical activity. Med Sci Sports Exerc. 2003;35:1196\u2013202.","DOI":"10.1249\/01.MSS.0000074446.02192.14"},{"key":"162515","doi-asserted-by":"crossref","unstructured":"Zhao SG, Alexander NB, Djuric Z, Zhou J, Tao Y, Schipper M, et al. Maintaining physical activity during head and neck cancer treatment: results of a pilot controlled trial. Head Neck. 2016;38:E1086\u201396.","DOI":"10.1002\/hed.24162"},{"key":"162516","doi-asserted-by":"crossref","unstructured":"Metwally MAH, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014;53:654\u201361.","DOI":"10.3109\/0284186X.2013.864050"},{"key":"162517","doi-asserted-by":"crossref","unstructured":"Fairman CM, L\u00f8nbro S, Cardaci TD, VanderVeen BN, Nilsen TS, Murphy AE. Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials. JCSM Rapid Commun. 2022;5:52\u201367.","DOI":"10.1002\/rco2.56"},{"key":"162518","doi-asserted-by":"crossref","unstructured":"Oates JE, Clark JR, Read J, Reeves N, Gao K, Jackson M, et al. Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:533\u201340.","DOI":"10.1001\/archotol.133.6.533"},{"key":"162519","doi-asserted-by":"crossref","unstructured":"Langius JA, Bakker S, Rietveld DH, Kruizenga HM, Langendijk JA, Weijs PJ, et al. Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy. Br J Cancer. 2013;109:1093\u20139.","DOI":"10.1038\/bjc.2013.458"},{"key":"162520","doi-asserted-by":"crossref","unstructured":"Yu Y, Yan L, Huang T, Wu Z, Liu J. Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients. Aging. 2024;16:5354\u201369.","DOI":"10.18632\/aging.205652"},{"key":"162521","doi-asserted-by":"crossref","unstructured":"Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1992\u20138.","DOI":"10.1200\/JCO.2008.20.2853"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45545\/54779","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45545\/54780","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45545\/54779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:27:09Z","timestamp":1783679229000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2026.45545","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}